ASCO 2024 – Laura’s crossover conundrum
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
ASCO 2024 – Krazati looks more similar than different to Lumakras
Meanwhile, Lilly gets in on the next-gen KRAS action.
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
ASCO 2024 – Summit peaks on ivonescimab surprise
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
ASCO 2024 – J&J flies towards a more convenient Rybrevant
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
ASCO 2024 preview – more questions for BioNTech
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
